Scientific deep-dive
GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not
In a controlled case series of five people with chronic spinal cord injury, three on weekly semaglutide lost weight, fat mass and visceral fat over 26 weeks while the two untreated participants gained on every measure.
Almost no obesity research enrolls people with chronic spinal cord injury, which leaves a group whose standard weight-loss advice depends on mobility they do not have. The one study we could find is a controlled case series: three people received weekly semaglutide for 26 weeks and two did not. The treated three lost weight, fat mass and visceral fat. The untreated two gained all three.[1] Five people make a very small study, but it is the best evidence that exists for this population.
What was done
The study was an open-label, randomized drug intervention case series at a VA medical center and a rehabilitation institute. Five individuals with chronic spinal cord injury who met criteria for obesity and abnormal carbohydrate metabolism were assigned to weekly subcutaneous semaglutide or to no treatment for 26 weeks. Body composition was measured by DXA at baseline and at the end.[1]
| Semaglutide (n = 3) | No treatment (n = 2) | |
|---|---|---|
| Total body weight | −6 kg | +3.3 kg |
| Fat tissue mass | −4.4 kg | +4.5 kg |
| Total body fat % | −1.7% | +2.5% |
| Visceral adipose tissue | −674 cm³ | +991 cm³ |
| Fasting plasma glucose | −17 mg/dL | +11 mg/dL |
| HbA1c | −0.2% | +0.3% |
In every row the two groups move in opposite directions, which is why a study this small is worth reporting at all. The treated group improved, and the untreated group got worse over the same half-year on every measure taken.
Why the control arm is the interesting half
After spinal cord injury, body composition tends to shift toward fat, including visceral fat, through mechanisms that have little to do with willpower and a great deal to do with reduced muscle mass and altered energy expenditure. The control participants’ deterioration over 26 weeks is consistent with that being the default direction of travel.
That reframes what a treatment would need to achieve. In a population drifting toward more visceral fat and worse glycemia, an intervention that merely holds the line would be doing something. This one appeared to reverse it, in three people.
What it does not answer
- Whether the effect holds in a larger group, or over longer than 26 weeks.
- How muscle is affected. DXA measured fat tissue mass, and lean tissue is already reduced in this population, but this study did not put muscle at its center.
- How the gastrointestinal side effects of these drugs interact with the bowel management routines many people with SCI depend on. That is a practical question and this study does not address it.
- Nothing here is a reason to change anything without the clinician who manages your injury. Autonomic and bowel considerations after SCI are specific, and general drug advice does not cover them.
For what the body-composition literature measures in the general population, and how rarely it measures function, see what the body-composition studies measured.
Frequently Asked Questions
References
- 1.Cirnigliaro CM, La Fountaine MF, Sauer SJ, et al. Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series The Journal of Spinal Cord Medicine. 2024. PMID: 37158751.
Compare the sellers
Related research
GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence
A phase 2b randomized trial found once-weekly semaglutide cut abdominal visceral fat by about 30.6% over 32 weeks in people with HIV-associated lipohypertrophy, alongside a 9.3% fall in psoas muscle volume that did not cost measurable function.
6 min read
Muscle Volume Versus Muscle Function on a GLP-1
Psoas muscle volume fell 9.3% over 24 weeks while chair-rise time and walking speed both edged better. Mass and function moved in opposite directions in the same people, and only one of them is what anybody wants.
6 min read
Protein Targets and the Lab Panel
At least 1.2 g of protein per kg daily, 0.3–0.4 g/kg per meal, and a short lab panel: vitamin D, B12, iron studies, folate and zinc, plus thiamin in high-risk patients. The upper protein target excludes chronic kidney disease.
5 min read
MK-677: A Real Trial in Eight People, and a Liver Report
A 1998 randomized crossover trial found MK-677 reversed diet-induced protein catabolism, moving nitrogen balance from -2.67 to +0.31 g/day. It enrolled eight people and measured a proxy. A 2025 case report describes liver injury after two months of use.
5 min read
Plant-Based Protein on a GLP-1: What Closes the Gap, and Why the Drug Widens It
Across a full day at high protein intake a vegan diet matched an omnivorous one for muscle. Per meal, an omnivorous meal produced about 47% more muscle protein synthesis than a vegan one, and a GLP-1 works against the intake that closes the gap.
7 min read
Exercise Plus a GLP-1: What Each One Actually Changes
In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.
6 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
From $79/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →HumeCare+
An oral route if you will not self-inject
From $199/mo
Get started →